Clinical trials: WM
Waldenström Macroglobulinemia (WM)
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia
This study is a prospective phase II clinical trial designed to evaluate the deep response rate of the ZBR regimen (zanubrutinib combined with reduced-dose bendamustine and CD20 Monoclonal Antibody ) in treatment-naïve…
- Trial name
- ZBR in WM (NCT07259122)
- Testing
- Zaunbrutinib, Bendamustine and Rituximab for induction therapy, Zanubrutinib mono therapy for maintenance treatment
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Advanced Solid Tumor, Metastatic Solid Tumor
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Lung Cancer, Colorectal Cancer
- Trial name
- NCT05872867
- Testing
- WM-A1-3389, Pembrolizumab
- Where
- 2 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Wellmarker Bio
Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be…
- Trial name
- NCT04440059
- Testing
- ICP-022
- Where
- 16 sites in China
- Volunteers
- 47 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Waldenstrom Macroglobulinemia
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
This research study is studying a targeted therapy as a possible treatment for relapsed or refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention ABT-199.
- Trial name
- NCT02677324
- Testing
- ABT199
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Dana-Farber Cancer Institute
Obesity, Weight Loss
Longitudinal Effects of a Commercial Digital Weight Management Program on Weight Loss
This randomized controlled trial (RCT) will test how well a fully remote weight management program (Noom Weight) helps adults with overweight or obesity (BMI 25-45) achieve weight loss in both the short-term (16 weeks) and the…
- Trial name
- NCT06666842
- Testing
- Noom Weight, Educational Control
- Where
- United States
- Volunteers
- 412 people
- Sponsor
- Noom Inc.
Stroke
Efficiency Study of Traditional Chinese Medicine (TCM) Versus Western Medicine (WM) on Ischemic Stroke
Complex project of Traditional Chinese Medicine (TCM) with Western Medicine (WM) project under stroke unit mode contrast,assuming that the efficiency of TCM on early rehabilitation and secondary prevention of ischemic stroke is…
- Trial name
- NCT00843765
- Testing
- acupuncture, massage and basic TCM treatment, rehabilitation and WM basic treatment
- Where
- China
- Volunteers
- 1,151 people
- Sponsor
- China Academy of Chinese Medical Sciences
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Waldenstrom Macroglobulinemia
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
The purpose of this study is to evaluate the efficacy of ibrutinib based on overall response rate (ORR) (partial response [PR] or better) by investigator assessment per the modified Consensus Response Criteria from the Sixth…
- Trial name
- NCT04042376
- Testing
- Ibrutinib
- Where
- 6 sites in China
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Working Memory, Inhibitory Control
BID WM Digital Intervention in Aging
The goal of this clinical trial is to learn if engaging with an digital intervention may improve cognitive function. The main questions it aims to answer are: 1.
- Conditions
- Working Memory, Inhibitory Control, Mild Cognitive Impairment (MCI), Aging
- Trial name
- NCT06918704
- Testing
- Coherence, Worder
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Relapsed/Refractory B-cell Malignancies
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: Identify the recommended dose of AC676 that can be given safely to…
- Trial name
- NCT05780034
- Testing
- AC676
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Accutar Biotechnology Inc
Waldenström Macroglobulinemia (WM)
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
This is a two-part, non-randomized, open-label Phase I clinical study. The research consists of: 1. A 3+3 dose-escalation phase to determine the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of the I+BR…
- Trial name
- NCT07169565
- Testing
- Ibrutinib, Bendamustine, Rituximab
- Volunteers
- 21 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Waldenström's Macroglobulinemia (WM)
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
This is a non-interventional, observational, retrospective and prospective multicenter Italian study, to describe treatment management and outcomes of Waldenström's Macroglobulinemia (WM) patients treated according to the Italian…
- Trial name
- NCT06441214
- Testing
- Zanubrutinib
- Where
- 23 sites in Italy
- Volunteers
- 212 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Waldenstrom's Macroglobulinemia
Teclistamab In Waldenstrom's Macroglobulinemia
The goal of this clinical trial is to assess the efficacy of teclistamab in participants with relapsed or refractory Waldenstrom's macroglobulinemia who have received prior therapy.
- Trial name
- NCT07791498
- Testing
- Teclistamab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Autism Spectrum Disorder
tDCS on Working Memory (WM) in Adults With ASD
This study will involve an experiment in individuals with Autism Spectrum Disorder (ASD) comparing their performance on a working memory task before, during and after non-invasive brain stimulation (tDCS) compared to a control…
- Trial name
- NCT03255837
- Testing
- Transcranial direct current stimulation (tDCS)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- NHS Greater Glasgow and Clyde
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).
- Conditions
- Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04043845
- Testing
- Ibrutinib, LY3214996
- Sponsor
- Dana-Farber Cancer Institute
Waldenstrom's Macroglobulinemia
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Pomalidomide is a newly discovered drug that may stop cancer cells from growing abnormally. Pomalidomide may also stimulate the immune system to fight the cancer cells and possibly improve the effectiveness of dexamethasone and…
- Trial name
- NCT01078974
- Testing
- pomalidomide, dexamethasone, rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Steven P. Treon, MD, PhD
B-cell Lymphoma
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
B-cell cancer is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- NCT04804254
- Testing
- ABBV-623, ABBV-992
- Where
- 5 sites in Israel, Puerto Rico and 1 more
- Volunteers
- 5 people
- Sponsor
- AbbVie
Waldenstrom Macroglobulinemia
Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)
Background: Waldenstrom macroglobulinemia (WM) is a type of blood cancer. It causes the blood to get thicker, which slows circulation and makes it harder to carry oxygen and other substances around the body.
- Trial name
- NCT07882173
- Testing
- epcoritamab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Waldenström's Macroglobulinemia (WM)
Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia
Current retrospective studies have demonstrated that achieving deep remission following treatment for Waldenström's macroglobulinemia (WM) correlates with prolonged survival.
- Trial name
- BRZ-WM (NCT06942507)
- Testing
- Zanubrutinib, Bendamustine + Rituximab
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Peking Union Medical College Hospital
Waldenström Macroglobulinemia (WM)
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.
- Trial name
- NCT02180724
- Testing
- Acalabrutinib (ACP-196)
- Where
- 38 sites in United States, France and 5 more
- Volunteers
- 107 people
- Sponsor
- Acerta Pharma BV